SUPN
Supernus Pharmaceuticals Inc
43.40$
-0.8%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +315.4% | +108.0% | +71.6% | +12.5% | +11.0% | -3.3% | -8.1% | -8.1% | -4.9% | +54.8% | -72.5% | |
| – | -0.8% | +160.5% | +239.0% | -13.1% | -5.7% | +172.4% | +79.7% | +162.4% | -0.8% | -5.2% | +12.0% | |
| – | +55.8% | +40.1% | +42.3% | +33.9% | +31.5% | +11.6% | +8.1% | -1.9% | +52.3% | +3.7% | +19.1% | |
| – | +148.3% | -671.6% | – | -76.1% | +26.4% | +79.0% | +21.6% | -153.6% | – | – | – | |
| – | – | -16.0% | +180.7% | -120.0% | – | -6,056.8% | – | -779.1% | – | – | – | |
| – | +254.8% | -23.8% | +26.6% | -58.4% | +224.2% | +26.1% | -40.7% | -79.9% | +33.7% | +31.6% | +84.6% | |
| – | +641.4% | -0.7% | +140.3% | +378.5% | -61.8% | -78.0% | +136.1% | +164.5% | – | -170.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +227.0% | +9.9% | +176.9% | +1,260.1% | -94.9% | +11.0% | +62.7% | +75.1% | -116.0% | – | – | |
| – | – | +0.0% | +0.0% | -2.6% | -100.2% | +0.0% | +17,146.3% | -100.0% | – | -100.0% | – | |
| – | +227.5% | +9.9% | +176.9% | +6,526.3% | -99.0% | -9.4% | -3,764.5% | -92.0% | +3,697.7% | – | -25.1% | |
| – | -165.7% | – | +3.1% | +171.2% | -111.8% | – | -179.4% | – | – | – | – | |
| – | +320.4% | +117.2% | +72.7% | +13.8% | +9.6% | -3.9% | -7.3% | -6.9% | -5.1% | +54.9% | -73.1% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.